Phospho-NCF1 (S359) antibodies are polyclonal rabbit-derived immunoglobulins (IgG) that recognize the phosphorylated state of NCF1 (p47-phox), a key component of the NADPH oxidase complex. Their specificity ensures detection only when Ser359 is phosphorylated, a modification critical for enzymatic activation. Key features include:
Catalog # | Host | Reactivity | Applications |
---|---|---|---|
ABIN6256289 | Rabbit | Human/Rat | WB, ELISA, IHC, IF |
bs-11445R | Rabbit | Rat/Predicted Human | WB, ELISA, IHC, IF |
STJ91104 | Rabbit | Human/Rat/Mouse | WB, ELISA, IHC, IF |
NCF1 phosphorylation at Ser359 is a critical regulatory step in NADPH oxidase activation. This enzyme complex generates reactive oxygen species (ROS) in phagocytes, essential for microbial killing but also implicated in oxidative stress-related diseases. The antibody enables researchers to:
Monitor activation dynamics: Track phosphorylation during immune responses or oxidative stress.
Study disease mechanisms: Investigate chronic granulomatous disease (CGD) or inflammation, where NCF1 mutations impair ROS production.
The antibody is validated for:
Assay | Dilution Range |
---|---|
Western Blotting | 1:300–5000 |
ELISA | 1:500–1000 |
Immunohistochemistry | 1:50–500 |
Immunofluorescence | 1:100–1000 |
Note: Cross-reactivity varies; STJ91104 extends to mouse, while bs-11445R is rat-focused with predicted human reactivity .
Recent studies using these antibodies have highlighted:
Oxidative signaling: Phosphorylation-dependent recruitment of NCF1 to membrane-bound subunits (e.g., NOX2) for ROS production .
Therapeutic targets: Modulating NCF1 phosphorylation to mitigate oxidative damage in neurodegenerative diseases .
Specificity: Ensure samples are treated to preserve phosphorylation (e.g., using phosphatase inhibitors).
Cross-reactivity: Validate species compatibility for murine or rat models.